Humacyte Inc is a biotechnology company focused on developing and commercializing innovative regenerative medicine products, specifically human acellular vessels (HAVs) designed for use in vascular surgeries. The company utilizes its proprietary tissue engineering platform to create off-the-shelf, biocompatible vessels that can address the limitations of traditional grafts in treating various vascular conditions. Humacyte aims to improve patient outcomes by providing solutions that enhance the healing process, reduce the risk of complications, and ultimately expand access to life-saving surgical treatments. Read More
Humacyte (NASDAQ: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues, announced it has entered into a securities purchase agreement with fundamental institutional investors for an oversubscribed registered direct offering totaling approximately $60 million. The Company will issue 28,436,018 shares of common stock and accompanying warrants to purchase an equal number of shares at $2.11 per unit. The warrants become exercisable 180 days after issuance, carry an exercise price of $2.11 per share, and expire April 7, 2031. Gross proceeds are expected to total $60 million before fees and expenses, with closing anticipated on or about Oct. 8, 2025. D. Boral Capital LLC is acting as exclusive placement agent for the offering.
NEW YORK CITY, NEW YORK / ACCESS Newswire / October 14, 2025 / On October 7, 2025, Humacyte, Inc. (Nasdaq:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, announced that it entered into a securities purchase agreement with certain fundamental institutional investors to purchase approximately $60,000,000 worth of its common stock and warrants in a Registered Direct offering.
Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Humacyte Inc (HUMA) Q2 2025 earnings show a revenue miss of 70%, with shares dropping ~9.9% pre-market. Hospital approvals grow, but commercial adoption lags.
Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
